Horm Metab Res 2015; 47(01): 78-83
DOI: 10.1055/s-0034-1395567
Endocrine Research
© Georg Thieme Verlag KG Stuttgart · New York

ALK5 Inhibition Maintains Islet Endothelial Cell Survival but does not Enhance Islet Graft Revascularisation or Function

A. J. F. King
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
C. E. Clarkin
2   Centre for Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK
,
A. L. F. Austin
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
L. Ajram
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
J. K. Dhunna
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
M. O. Jamil
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
S. I. Ditta
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
S. Ibrahim
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
Z. Raza
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
,
P. M. Jones
1   Diabetes Research Group, Division of Diabetes and Nutritional Sciences, King’s College, London, UK
› Author Affiliations
Further Information

Publication History

received 07 August 2014

accepted 29 October 2014

Publication Date:
27 November 2014 (online)

Abstract

Islet transplantation is a potential treatment for Type 1 diabetes but long term graft function is suboptimal. The rich supply of intraislet endothelial cells diminishes rapidly after islet isolation and culture, which affects the revascularisation rate of islets after transplantation. The ALK5 pathway inhibits endothelial cell proliferation and thus inhibiting ALK5 is a potential target for improving endothelial cell survival. The aim of the study was to establish whether ALK5 inhibition prevents the loss of intraislet endothelial cells during islet culture and thus improves the functional survival of transplanted islets by enhancing their subsequent revascularisation after implantation. Islets were cultured for 48 h in the absence or presence of 2 different ALK inhibitors: SB-431542 or A-83-01. Their vascular density after culture was analysed using immunohistochemistry. Islets pre-cultured with the ALK5 inhibitors were implanted into streptozotocin-diabetic mice for either 3 or 7 days and blood glucose concentrations were monitored and vascular densities of the grafts were analysed. Islets cultured with ALK5 inhibitors had higher vascular densities than control-cultured islets. Three days after implantation, endothelial cell numbers in islet grafts were minimal, irrespective of treatment during culture. Seven days after implantation, endothelial cells were evident within the islet grafts but there was no difference between control-cultured islets and islets pre-treated with an ALK5 inhibitor. Blood glucose concentrations were no different between the treatment groups. In conclusion, inhibition of ALK5 improved intraislet endothelial cell numbers after islet culture, but this effect was lost in the early post-transplantation period.

 
  • References

  • 1 Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes 2014; 7: 211-223
  • 2 Peiris H, Bonder CS, Coates PT, Keating DJ, Jessup CF. The beta-cell/EC axis: how do islet cells talk to each other?. Diabetes 2014; 63: 3-11
  • 3 Rackham CL, Dhadda PK, Chagastelles PC, Simpson SJ, Dattani AA, Bowe JE, Jones PM, King AJ. Pre-culturing islets with mesenchymal stromal cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice. Cytotherapy 2013; 15: 449-459
  • 4 Nyqvist D, Kohler M, Wahlstedt H, Berggren PO. Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes 2005; 54: 2287-2293
  • 5 Parr EL, Bowen KM, Lafferty KJ. Cellular changes in cultured mouse thyroid glands and islets of Langerhans. Transplantation 1980; 30: 135-141
  • 6 Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M, Sawada T, Matsumoto I, Zhang HJ, Sutherland DE, Bluestone JA. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplantat 2004; 4: 390-401
  • 7 Shapiro AM, Ricordi C, Hering B. Edmonton’s islet success has indeed been replicated elsewhere. Lancet 2003; 362: 1242
  • 8 Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, Pileggi A, Poggioli R, Ichii H, Khan A, Ferreira JV, Pugliese A, Esquenazi VV, Kenyon NS, Alejandro R. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 5: 2037-2046
  • 9 Kin T, Senior P, O’Gorman D, Richer B, Salam A, Shapiro AM. Risk factors for islet loss during culture prior to transplantation. Transpl Int 2008; 21: 1029-1035
  • 10 Goss JA, Schock AP, Brunicardi FC, Goodpastor SE, Garber AJ, Soltes G, Barth M, Froud T, Alejandro R, Ricordi C. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002; 74: 1761-1766
  • 11 Brissova M, Fowler M, Wiebe P, Shostak A, Shiota M, Radhika A, Lin PC, Gannon M, Powers AC. Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. Diabetes 2004; 53: 1318-1325
  • 12 Nyqvist D, Speier S, Rodriguez-Diaz R, Molano RD, Lipovsek S, Rupnik M, Dicker A, Ilegems E, Zahr-Akrawi E, Molina J, Lopez-Cabeza M, Villate S, Abdulreda MH, Ricordi C, Caicedo A, Pileggi A, Berggren PO. Donor islet endothelial cells in pancreatic islet revascularization. Diabetes 2011; 60: 2571-2577
  • 13 Olsson R, Carlsson PO. Better vascular engraftment and function in pancreatic islets transplanted without prior culture. Diabetologia 2005; 48: 469-476
  • 14 ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-869
  • 15 Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007; 102: 593-608
  • 16 Clarkin CE, King AJ, Dhadda P, Chagastelles P, Nardi N, Wheeler-Jones CP, Jones PM. Activin receptor-like kinase 5 inhibition reverses impairment of endothelial cell viability by endogenous islet mesenchymal stromal cells. Stem Cells 2013; 31: 547-559
  • 17 Liu Z, Kobayashi K, van Dinther M, van Heiningen SH, Valdimarsdottir G, van Laar T, Scharpfenecker M, Lowik CW, Goumans MJ, Ten Dijke P, Pardali E. VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J Cell Sci 2009; 122: 3294-3302
  • 18 Kerby A, Bohman S, Westberg H, Jones P, King A. Immunoisolation of islets in high guluronic acid barium-alginate microcapsules does not improve graft outcome at the subcutaneous site. Artif Org 2012; 36: 564-570
  • 19 Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74
  • 20 Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, Node M, Imamura T. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci 2005; 96: 791-800
  • 21 Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ. Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 2011; 54: 1127-1135
  • 22 Mattsson G, Jansson L, Carlsson PO. Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes 2002; 51: 1362-1366
  • 23 Wang X, Meloche M, Verchere CB, Ou D, Mui A, Warnock GL. Improving islet engraftment by gene therapy. J Transpl 2011; 2011: 594851
  • 24 Olerud J, Johansson M, Lawler J, Welsh N, Carlsson PO. Improved vascular engraftment and graft function after inhibition of the angiostatic factor thrombospondin-1 in mouse pancreatic islets. Diabetes 2008; 57: 1870-1877
  • 25 Johansson U, Rasmusson I, Niclou SP, Forslund N, Gustavsson L, Nilsson B, Korsgren O, Magnusson PU. Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes 2008; 57: 2393-2401
  • 26 King A, Lock J, Xu G, Bonner-Weir S, Weir GC. Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 2005; 48: 2074-2079
  • 27 Emamaullee JA, Shapiro AM. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 2006; 55: 1907-1914
  • 28 Sahraoui A, Jensen KK, Ueland T, Korsgren O, Foss A, Scholz H. Anakinra and tocilizumab enhance survival and function of human islets during culture: implications for clinical islet transplantation. Cell Transpl 2014; 23: 1199-1211
  • 29 Olsson R, Maxhuni A, Carlsson PO. Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis. Transplantation 2006; 82: 340-347
  • 30 Wu H, Mezghenna K, Marmol P, Guo T, Moliner A, Yang SN, Berggren PO, Ibanez CF. Differential regulation of mouse pancreatic islet insulin secretion and Smad proteins by activin ligands. Diabetologia 2014; 57: 148-156
  • 31 Reinert RB, Brissova M, Shostak A, Pan FC, Poffenberger G, Cai Q, Hundemer GL, Kantz J, Thompson CS, Dai C, McGuinness OP, Powers AC. Vascular endothelial growth factor-a and islet vascularization are necessary in developing, but not adult, pancreatic islets. Diabetes 2013; 62: 4154-4164